REpresentative Clinical Research- ADvancing Inclusivity in Europe (READI)

Chiesi Participation

Marisa Minetti – Chiara Mazzoli, 6th July 2026

MISSION & VALUES

Our aim
is to be recognized as a research-focused international Group, able to develop and commercialize innovative biopharmaceutical solutions to improve the quality of human life.

We wish
to maintain a high-quality entrepreneurial team characterized by self-con-fidence and a collaborative spirit.

Our goal
is to combine commitment to results with integrity, operating in a socially and envi-ronmentally responsible manner.

This is us

CHIESI'S FOUR CORE AREAS

Patients

READI

We are dedicated to making a meaningful impact on the lives of patients, their families, and caregivers.

Planet

We are committed to minimizing any po-tential damage our operations could have on the environment and conserving natu-ral resources.

People

We put people first by prioritizing the well-being, motivation, and development of everyone within our Organization and we invest in projects that strengthen local communities.

Prosperity

We promote a governance model rooted in ethics, transparency, and accountability.

COMPANY OVERVIEW

Business Areas

air

Asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), bronchiectasis, pulmonary arterial hypertension (PAH).

rare

Inborn errors of metabolism, rare hematologic and immunologic diseases, endo-metabolic disorders and dermatology.

care

Solid organ transplant, cardiovascular diseases, consumer healthcare / over the counter, neonatal respiratory distress syndrome (nRDS), primary apnea of premature newborns.

Research-focused

1st among the Italian pharmaceutical companies for R&D investments*

Among the **TOP 15** European pharma companies*

€ 3.6 BILLION
in revenues

R&D investments
24.4% of revenues

6,324 worldwide patents
Chiesi portfolio (until 12/31/2025)

With 36 new registered patents, in 2025 Chiesi was confirmed the

Benefit Corporation in Italy (Società Benefit), France (Société à Mission), United States and Colombia (Empresa de Beneficio e Interés Colectivo)

Certified B Corp since 2019. Successfully recertified in 2025 with 117,5 points in the BIA score

Researchers at global level
800
Research & Development centers
7

* European Commission – 2023 EU Industrial R&D Investment Scoreboard.
** The total of employees includes long-term employee absences and therefore differs from the total of employees reported in the Consolidated Financial Statement (equal to 7,065 at 31st December 2024) in which long-term employee absences are excluded, and it differs from the total workforce (equal to 7,542 at 31st December 2024) in which external collaborators (field force contractors and ad interim employees) of the Group are included and long-term employee absences are excluded.

CONSORTIUM

The consortium is coordinated by the Servicio Madrileño de Salud (SERMAS), through Hospital Universitario La Paz, as the Project Coordinator, Novartis as the Project Lead, and supported by The Synergist as the Digital & Sustainability Coordinator.

80 Partners

18 Countries

€66,8M Budget

6 YEARS

Vision: A more representative, inclusive, and impactful clinical research ecosystem across Europe

MISSION

The READI Project works to reshape the clinical studies ecosystem in Europe, allowing everyone - especially underserved and underrepresented (US/UR) populations - to access, participate and benefit from health innovations. READI will ensure that clinical research engages with and benefits all stakeholders, including patients, healthcare professionals, study sites, patient organizations, sponsors, regulatory agencies, HTA agencies and ethics committees.

Unequal access to health innovations for patients across Europe

Significant knowledge gaps in clinical research that affect healthcare for everyone

Preventing many UR/US populations from participating in clinical studies, reinforcing disparities in healthcare innovation and outcomes

Co-funded by the European Union
innovative health initiative

This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101166227. The JU receives support from the European Union's Horizon Europe research and innovation programme and COCIR, EFPIA, EuropaBio, MedTech Europe, Vaccines Europe, and Medicines and Healthcare Products Regulatory Agency and Breakthrough T1D.
This project is also supported by UKRI (UK Research and Innovation) under grant agreement No 10152425 for National Institute for Health and Care Excellence and grant agreement No 31052024 for The University Court of the University of Aberdeen.

READI

READI PARTICIPATION DECISION

Pros & cons of participating in READI

PROS — strategic value

1. **Access to a leading ecosystem**
   Join 80 partners across 18 countries shaping inclusive clinical research practices.
2. **Strong fit with Chiesi values**
   Reinforces patient-first, health equity and B Corp commitments through visible collaboration.
3. **Capability building**
   Leverage training, tools, digital platform and site-readiness work for more inclusive trials.
4. **More representative evidence**
   More representative recruitment can improve trial relevance, data quality and healthcare impact.

CONS — watchouts to manage

1. **Scope and budget discipline**
   Expansion beyond current WP commitments needs clear governance, effort tracking and reporting alignment.
2. **Resource load**
   A six-year consortium means meetings, deliverable reviews and internal coordination over time.
3. **Operational complexity**
   Inclusive studies require tailored outreach, site capability, cultural competence and GDPR safeguards.
4. **Indirect ROI**
   Benefits may be long-term unless outputs are translated into Chiesi processes and study planning.

Suggested stance Participate selectively, with WP owners, agreed effort and a clear internal adoption plan.